

Byondis Initiates Ph I trials of ADC as treatment of HER2-Expressing Solid Tumors

25 August 2020 | News

First patients dosed in Phase I study of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in combination with niraparib in patients with a HER2-expressing locally advanced or metastatic solid tumor

byondis | Creating Precision Medicines



A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors (SYD985.004) will enroll up to 120 patients who progressed on standard therapy or for whom no standard therapy of proven benefit exists. The first part of the study is taking place in leading European oncology centers in Belgium, United Kingdom and the Netherlands. Leading centers in France, Spain and Poland will join this trial at a later stage.

“We are excited to move to the clinical study phase of [vic-]trastuzumab duocarmazine in combination with PARP inhibitor niraparib,” said Byondis CEO Marco Timmers, Ph.D. “Preclinical investigation of SYD985 in combination with PARP inhibitors in HER2-expressing tumor cells suggested synergistic effects and we hope to confirm these effects in the clinic.”

[The attached release provides more details.](#) Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications. SYD985 is Byondis’ most advanced ADC, in development for the treatment of a range of HER2-expressing tumor types including breast and endometrial cancer.

Please let us know if you would like to learn more about Byondis or their investigational ADCs. We would be happy to arrange an interview with Byondis CEO Marco Timmers, Ph.D.